155 related articles for article (PubMed ID: 16170030)
1. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.
Brezak MC; Quaranta M; Contour-Galcera MO; Lavergne O; Mondesert O; Auvray P; Kasprzyk PG; Prevost GP; Ducommun B
Mol Cancer Ther; 2005 Sep; 4(9):1378-87. PubMed ID: 16170030
[TBL] [Abstract][Full Text] [Related]
2. A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC; Quaranta M; Mondésert O; Galcera MO; Lavergne O; Alby F; Cazales M; Baldin V; Thurieau C; Harnett J; Lanco C; Kasprzyk PG; Prevost GP; Ducommun B
Cancer Res; 2004 May; 64(9):3320-5. PubMed ID: 15126376
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly.
Cazales M; Boutros R; Brezak MC; Chaumeron S; Prevost G; Ducommun B
Mol Cancer Ther; 2007 Jan; 6(1):318-25. PubMed ID: 17237290
[TBL] [Abstract][Full Text] [Related]
4. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.
Brezak MC; Valette A; Quaranta M; Contour-Galcera MO; Jullien D; Lavergne O; Frongia C; Bigg D; Kasprzyk PG; Prevost GP; Ducommun B
Int J Cancer; 2009 Mar; 124(6):1449-56. PubMed ID: 19065668
[TBL] [Abstract][Full Text] [Related]
5. Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
Capasso A; Cerchia C; Di Giovanni C; Granato G; Albano F; Romano S; De Vendittis E; Ruocco MR; Lavecchia A
Oncotarget; 2015 Nov; 6(37):40202-22. PubMed ID: 26474275
[TBL] [Abstract][Full Text] [Related]
6. Effective Pharmacophore for CDC25 Phosphatases Enzyme Inhibitors: Newly Synthesized Bromothiazolopyrimidine Derivatives.
El-Shahat M; Salama MAM; El-Farargy AF; Ali MM; Ahmed DM
Mini Rev Med Chem; 2021; 21(1):118-131. PubMed ID: 32560601
[TBL] [Abstract][Full Text] [Related]
7. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
Brisson M; Nguyen T; Vogt A; Yalowich J; Giorgianni A; Tobi D; Bahar I; Stephenson CR; Wipf P; Lazo JS
Mol Pharmacol; 2004 Oct; 66(4):824-33. PubMed ID: 15231869
[TBL] [Abstract][Full Text] [Related]
8. A fission yeast strain expressing human CDC25A phosphatase: a tool for selectivity studies of pharmacological inhibitors of CDC25.
Mondesert O; Lemaire M; Brezak MC; Galera-Contour MO; Prevost G; Ducommun B; Bugler B
Curr Genet; 2004 May; 45(5):283-8. PubMed ID: 14727060
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.
Lavecchia A; Di Giovanni C; Novellino E
Expert Opin Ther Pat; 2010 Mar; 20(3):405-25. PubMed ID: 20166845
[TBL] [Abstract][Full Text] [Related]
10. A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.
Aoyagi Y; Masuko N; Ohkubo S; Kitade M; Nagai K; Okazaki S; Wierzba K; Terada T; Sugimoto Y; Yamada Y
Cancer Sci; 2005 Sep; 96(9):614-9. PubMed ID: 16128747
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.
Song Y; Lin X; Kang D; Li X; Zhan P; Liu X; Zhang Q
Eur J Med Chem; 2014 Jul; 82():293-307. PubMed ID: 24922544
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913
[TBL] [Abstract][Full Text] [Related]
13. Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.
Kolb S; Mondésert O; Goddard ML; Jullien D; Villoutreix BO; Ducommun B; Garbay C; Braud E
ChemMedChem; 2009 Apr; 4(4):633-48. PubMed ID: 19212959
[TBL] [Abstract][Full Text] [Related]
14. Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.
Brault L; Bagrel D
Life Sci; 2008 Jan; 82(5-6):315-23. PubMed ID: 18191419
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: effect of dimerisation on phosphatase inhibition.
Sarkis M; Tran DN; Kolb S; Miteva MA; Villoutreix BO; Garbay C; Braud E
Bioorg Med Chem Lett; 2012 Dec; 22(24):7345-50. PubMed ID: 23141909
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries.
Tao Y; Hao X; Jing L; Sun L; Cherukupalli S; Liu S; Wu G; Xu S; Zhang X; Shi X; Song Y; Liu X; Zhan P
Bioorg Chem; 2021 Oct; 115():105254. PubMed ID: 34426152
[TBL] [Abstract][Full Text] [Related]
17. In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.
Kiyokawa H; Ray D
Anticancer Agents Med Chem; 2008 Dec; 8(8):832-6. PubMed ID: 19075565
[TBL] [Abstract][Full Text] [Related]
18. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
19. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.
Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P
Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869
[TBL] [Abstract][Full Text] [Related]
20. A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death.
Bana E; Sibille E; Valente S; Cerella C; Chaimbault P; Kirsch G; Dicato M; Diederich M; Bagrel D
Mol Carcinog; 2015 Mar; 54(3):229-41. PubMed ID: 24155226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
